MedPath

Clinical Study to evaluate the effectiveness of Linga chendooram in the management of Uthiravatha suronitham (Rheumatoid arthritis)

Phase 2
Conditions
Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
Registration Number
CTRI/2023/09/057492
Lead Sponsor
I
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Onset of arthritis after the age of 16 years

Positive for rheumatoid factor (RF)

Anti - CCP

Either an erythrocyte sedimentation rate (ESR) of greater than 30 mm/hr OR

C-reactive protein level greater than 1.0 mg/dl (normal less than 0.4)

Diagnosis of Uthira Vatha Suronitham, as defined by fulfilling at least more than two articular involvements

Minor

Morning stiffness

Willing to take study medication

Willing to follow diet restriction

Patients giving informed consent (Signed or oral witnessed, according to local regulations) before any Protocol specific

procedures.

Exclusion Criteria

Uncontrolled Diabetes Mellitus

Uncontrolled Hypertension

Cardiac disease

Renal disease

Neurological disorders

Pregnancy and lactation

History of alcohol or substance abuse

Active infection, or chronic or persistent infection that might

worsen with immunosuppressive treatment

Patients who have already participated in a new drug study in

the past 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction of pain and swelling of the jointsTimepoint: Baseline and 12 th week
Secondary Outcome Measures
NameTimeMethod
To study the clinical laboratory parameters related to RA RA Factor CRP ESR etcTimepoint: Baseline ad 12th wek
© Copyright 2025. All Rights Reserved by MedPath